No Prescription |
 |
 | ||
|
Moxif Avelox |
|
| ||
No Prescription » Prescription Drugs 11 » Moxif Avelox Moxifloxacin is in a class of drugs called fluoroquinolone antibiotics. It works by stopping the life cycle of bacteria. It is used to eliminate certain bacteria that cause infections in your lungs and sinuses. Antibiotics will not work for colds flu or other viral infections.Moxifloxacin comes as tablet to take by mouth. It is usually taken once a day for 5 to 10 days. Moxifloxacin tablets should be swallowed whole with a full glass of water. It can be taken with or without food. Buy Moxif Avelox and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About Moxif Avelox: Product Type: Prescription Drugs 11 Moxif ( Avelox Generic moxifloxacin ) Moxif (Avelox Generic moxifloxacin) Avelox Generic moxifloxacin 400mg Avelox Generic moxifloxacin Moxif
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
